ENTRADA THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $30.00K, a 50.00% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $100.00K, a 71.43% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $8.00K, a 97.90% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $20.00K, a 98.19% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $425.00K, a 84.72% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $2.78M, a 134.37% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $1.19M, a 508.72% increase from fiscal 2022.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $195.00K, a 52.44% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $30.00K 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $100.00K 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $425.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | $8.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $20.00K 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $350.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $2.78M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $381.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.10M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $206.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $1.19M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $368.00K 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $257.00K 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $129.00K 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $195.00K 10-K · filed 2024-03-13 | |
| 2022-09-30 | $60.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $11.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $50.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $410.00K 10-K · filed 2023-03-06 | |
| 2021-09-30 | $106.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $212.00K 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $29.00K 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $214.00K 10-K · filed 2022-03-15 | |
| 2020-06-30 | $83.00K 10-Q · filed 2021-12-09 | |
| 2020-03-31 | $1.00K 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |